ArticleNeurology(R) neuroimmunology & neuroinflammation2025
Obesity Affects Disease Activity and Progression, Cognitive Functioning, and Quality of Life in People With Multiple Sclerosis.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Glucagon-Like Peptide-1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review.Annals of clinical and translational neurology · 2026Review
- Effectiveness of a self-management educational program among people with multiple sclerosis: a pre-test post-test intervention study.The Journal of the Egyptian Public Health Association · 2026Article
- Genetic modification of obesity-associated disability progression in multiple sclerosis.Journal of neurology · 2026Article
- Targeting progressive multiple sclerosis: Toward mechanism-informed precision medicine.Journal of internal medicine · 2026Review
- Body Composition Analysis in Young Patients with Recent Diagnosis of Multiple Sclerosis: An Exploratory Study.Journal of clinical medicine · 2026Article
- Clinical and Modifiable Factors Associated With Disability and Relapse in MOGAD: A Multicentre Cohort Study.Annals of clinical and translational neurology · 2026Article
- Smoking, Comorbidities, and Low Sun Exposure Are Associated with Clinical and Radiological Outcomes in Patients with Multiple Sclerosis-A Four-Year Observational Cohort Study.Journal of clinical medicine · 2026Article
- Preventive strategies in neuroimmunology.Neurological research and practice · 2026Review
- Is Obesity a Modifiable Risk Factor in Multiple Sclerosis? Mechanistic Insights into Neuroinflammation and Oxidative Damage.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Multiple sclerosis and the limits of classical autoimmune theory.Frontiers in immunology · 2026Review
- The association between BMI and cognition, disability, and quality of life markers in multiple sclerosis: DISCOMS secondary analysis.Therapeutic advances in neurological disorders · 2026Article
- Comorbidity and modifiable risk factors in multiple sclerosis.Therapeutic advances in neurological disorders · 2026Review
- A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.Frontiers in immunology · 2026Article
- Smoking Habits, Physical Activity and BMI as Predictors of Cognitive and Affective Function in Patients with Prostate Cancer.Research and reports in urology · 2026Article
- The Prevalence and Characteristics of Obstructive Sleep Apnea Among Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis.Journal of central nervous system disease · 2026Article
- Targeting Lifestyle in CNS Inflammatory Demyelinating Diseases: Insights from Diet and Exercise as Potential Disease Modifiers.Brain sciences · 2025Review
- Determinants and prognostic value of onset symptoms in multiple sclerosis.Journal of neurology · 2025Article
- Angiogenesis and Hypoxia Biomarkers Are Dysregulated in Progressive Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Are pNF-H, IL-6, BDNF, and NSP Reliable Biomarkers of Cognitive Function in Prostate Cancer Patients?International journal of molecular sciences · 2025Article
- Sex-Related Differences in Lifestyle Factors Affecting Multiple Sclerosis Susceptibility and Disease Progression.Brain sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesWhile obesity is a known risk factor of the development of multiple sclerosis (MS), its impact on MS disease progression remains unclear. We aimed to investigate the influence of body mass index (BMI) on disease activity and progression, cognitive performance, and health-related quality of life in patients with MS.
methodsPatients from an incident population-based case-control study (n = 3,249) were categorized based on BMI status at diagnosis and followed up after diagnosis through the Swedish MS registry. Outcomes included changes in the Expanded Disability Status Scale (EDSS), Multiple Sclerosis Impact Scale 29, and Symbol Digit Modalities Test. The mean follow-up time was 10.6 years (SD 6.1). Linear mixed models were used to analyze long-term changes while Cox regression models assessed the risk of 24-week confirmed disability worsening, time to reach EDSS score 3 and EDSS score 4, the appearance of new lesions on MRI, patient-reported physical and psychological worsening, and processing speed worsening.
resultsObesity, compared with healthy weight, was associated with a 0.02-point faster annual increase in the EDSS score (β for EDSS score x time 0.02, 95% CI 0.00-0.04). In addition, obesity was linked to a higher risk of reaching EDSS score 3 (HR 1.43, 95% CI 1.17-1.75) and EDSS score 4 (HR 1.40, 95% CI 1.07-1.73) and an increased risk of physical and psychological worsening. New lesions on MRI were more frequent among those with overweight and obesity, compared with those with healthy weight (HR 1.21, 95% CI 1.02-1.44 and HR 1.29, 95% CI 1.03-1.62, respectively). Among those who had not changed BMI group during follow-up, the associations between obesity and unfavorable outcomes became more pronounced, and the HR of cognitive disability worsening was 1.51 (95% CI 1.09-2.09) among those with obesity, compared with nonobese participants. DISCUSSION: In participants with MS, obesity was associated with faster disease progression, poorer health-related quality of life, and more rapid cognitive decline. Both overweight and obesity were associated with higher MRI activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.